{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:52:46Z","timestamp":1764172366192,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of North Carolina at Chapel Hill Department of Radiology"},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health &amp; Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001111"],"award-info":[{"award-number":["UL1TR001111"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Certain matrix metalloproteinases (MMPs) have the ability to degrade collagen IV, a main component of the breast lobular basement membrane. In this cross-sectional study, we evaluated expression of MMPs 2, 9, and 14 and collagen IV in LCIS and adjacent normal breast tissue among LCIS patients without invasive breast cancer to determine whether expression differed between benign and preinvasive breast epithelial tissue. A total of 64 LCIS patients, diagnosed 2004\u20132014, were included; 44 had sufficient paired normal tissue for analysis. Marker epithelial expression was measured using immunofluorescence and quantified using the H score (MMPs) or pixel intensity (collagen IV). Associations were evaluated using the Spearman correlation or the Wilcoxon signed-rank test. In LCIS and normal tissue, there was a strong correlation between MMP2 and MMP14 expression (LCIS r\u2009=\u20090.69, normal r\u2009=\u20090.81, both P\u2009&lt;\u20090.01). Other pairwise correlations were moderate to weak (range: LCIS r\u2009=\u20090.32\u20130.47, normal r\u2009=\u20090.19\u20130.32). For all markers, expression was lower in LCIS vs. normal tissue (all P\u2009\u2264\u20090.05). In sum, collagenase MMPs were expressed in normal breast and LCIS lesions of LCIS patients. However, expression was not higher in LCIS compared with normal tissue, suggesting collagenase MMP expression does not increase as breast tissue gains a more proliferative phenotype.<\/jats:p>","DOI":"10.1038\/s41598-019-48602-6","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T10:04:52Z","timestamp":1568714692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Quantitative expression of MMPs 2, 9, 14, and collagen IV in LCIS and paired normal breast tissue"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-5993","authenticated-orcid":false,"given":"Sarah J.","family":"Nyante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengteng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-2269","authenticated-orcid":false,"given":"Xianming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily F.","family":"Ozdowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"48602_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrclinonc.2015.8","volume":"12","author":"M Morrow","year":"2015","unstructured":"Morrow, M., Schnitt, S. J. & Norton, L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol 12, 227\u2013238 (2015).","journal-title":"Nat Rev Clin Oncol"},{"key":"48602_CR2","unstructured":"Howlader, N. et al. SEER cancer statistics review, 1975\u20132013, National Cancer Institute, Bethesda, MD. Available from: http:\/\/seer.cancer.gov\/csr\/1975_2013\/, based on November 2015 SEER data submission, posted April 2016."},{"key":"48602_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3322\/caac.21321","volume":"65","author":"EM Ward","year":"2015","unstructured":"Ward, E. M. et al. Cancer statistics: Breast cancer in situ. CA Cancer J Clin 65, 481\u2013495 (2015).","journal-title":"CA Cancer J Clin"},{"key":"48602_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0580-5","volume":"17","author":"GJ Logan","year":"2015","unstructured":"Logan, G. J. et al. Molecular drivers of lobular carcinoma in situ. Breast Cancer Res 17, 76 (2015).","journal-title":"Breast Cancer Res"},{"key":"48602_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/CEJ.0b013e3282f75e5d","volume":"17","author":"N Afonso","year":"2008","unstructured":"Afonso, N. & Bouwman, D. Lobular carcinoma in situ. Eur J Cancer Prev 17, 312\u2013316 (2008).","journal-title":"Eur J Cancer Prev"},{"issue":"4","key":"48602_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.molonc.2014.12.005","volume":"9","author":"Victor P. Andrade","year":"2014","unstructured":"Andrade, V. P. et al. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol 9, 772\u2013782 (2015).","journal-title":"Molecular Oncology"},{"key":"48602_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3222","volume":"14","author":"VP Andrade","year":"2012","unstructured":"Andrade, V. P. et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res 14, R103 (2012).","journal-title":"Breast Cancer Res"},{"key":"48602_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-007-9557-0","volume":"107","author":"S Aulmann","year":"2008","unstructured":"Aulmann, S. et al. Clonality of lobular carcinoma in situ (lcis) and metachronous invasive breast cancer. Breast Cancer Res Treat 107, 331\u2013335 (2008).","journal-title":"Breast Cancer Res Treat"},{"key":"48602_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/mp.53.3.118","volume":"53","author":"H Buerger","year":"2000","unstructured":"Buerger, H. et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol 53, 118\u2013121 (2000).","journal-title":"Mol Pathol"},{"key":"48602_CR10","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1002\/cncr.20273","volume":"100","author":"ES Hwang","year":"2004","unstructured":"Hwang, E. S. et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 100, 2562\u20132572 (2004).","journal-title":"Cancer"},{"key":"48602_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tcb.2008.08.007","volume":"18","author":"RG Rowe","year":"2008","unstructured":"Rowe, R. G. & Weiss, S. J. Breaching the basement membrane: Who, when and how? Trends Cell Biol 18, 560\u2013574 (2008).","journal-title":"Trends Cell Biol"},{"key":"48602_CR12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1046\/j.1365-2559.1999.0820a.x","volume":"35","author":"SA Hoda","year":"1999","unstructured":"Hoda, S. A., Prasad, M. L., Moore, A., Hoda, R. S. & Giri, D. Microinvasive carcinoma of the breast: Can it be diagnosed reliably and is it clinically significant? Histopathology 35, 468\u2013470 (1999).","journal-title":"Histopathology"},{"key":"48602_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1365-2559.2000.09738.x","volume":"37","author":"AJ Howat","year":"2000","unstructured":"Howat, A. J., Armour, A. & Ellis, I. O. Microinvasive lobular carcinoma of the breast. Histopathology 37, 477\u2013478 (2000).","journal-title":"Histopathology"},{"key":"48602_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/(SICI)1096-9098(199801)67:1<41::AID-JSO9>3.0.CO;2-M","volume":"67","author":"T Nemoto","year":"1998","unstructured":"Nemoto, T. et al. Lobular carcinoma in situ with microinvasion. J Surg Oncol 67, 41\u201346 (1998).","journal-title":"J Surg Oncol"},{"key":"48602_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/jcp.45.10.936","volume":"45","author":"J Coyne","year":"1992","unstructured":"Coyne, J., Hobbs, F. M., Boggis, C. & Harland, R. Lobular carcinoma in a mammary hamartoma. J Clin Pathol 45, 936\u2013937 (1992).","journal-title":"J Clin Pathol"},{"key":"48602_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10911-010-9177-x","volume":"15","author":"ES Radisky","year":"2010","unstructured":"Radisky, E. S. & Radisky, D. C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 15, 201\u2013212 (2010).","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"48602_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF00666168","volume":"31","author":"EW Thompson","year":"1994","unstructured":"Thompson, E. W. et al. Collagen induced mmp-2 activation in human breast cancer. Breast Cancer Res Treat 31, 357\u2013370 (1994).","journal-title":"Breast Cancer Res Treat"},{"key":"48602_CR18","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1074\/jbc.270.10.5331","volume":"270","author":"AY Strongin","year":"1995","unstructured":"Strongin, A. Y. et al. Mechanism of cell surface activation of 72-kda type iv collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270, 5331\u20135338 (1995).","journal-title":"J Biol Chem"},{"key":"48602_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2","volume":"189","author":"JL Jones","year":"1999","unstructured":"Jones, J. L., Glynn, P. & Walker, R. A. Expression of mmp-2 and mmp-9, their inhibitors, and the activator mt1-mmp in primary breast carcinomas. J Pathol 189, 161\u2013168 (1999).","journal-title":"J Pathol"},{"key":"48602_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4149\/neo_2014_054","volume":"61","author":"V Puzovic","year":"2014","unstructured":"Puzovic, V., Brcic, I., Ranogajec, I. & Jakic-Razumovic, J. Prognostic values of ets-1, mmp-2 and mmp-9 expression and co-expression in breast cancer patients. Neoplasma 61, 439\u2013446 (2014).","journal-title":"Neoplasma"},{"key":"48602_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12032-011-9984-y","volume":"29","author":"I Ranogajec","year":"2012","unstructured":"Ranogajec, I., Jakic-Razumovic, J., Puzovic, V. & Gabrilovac, J. Prognostic value of matrix metalloproteinase-2 (mmp-2), matrix metalloproteinase-9 (mmp-9) and aminopeptidase n\/cd13 in breast cancer patients. Med Oncol 29, 561\u2013569 (2012).","journal-title":"Med Oncol"},{"key":"48602_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1023\/A:1021371028777","volume":"77","author":"L Nakopoulou","year":"2003","unstructured":"Nakopoulou, L. et al. Mmp-2 protein in invasive breast cancer and the impact of mmp-2\/timp-2 phenotype on overall survival. Breast Cancer Res Treat 77, 145\u2013155 (2003).","journal-title":"Breast Cancer Res Treat"},{"key":"48602_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-004-0714-4","volume":"89","author":"A Sivula","year":"2005","unstructured":"Sivula, A. et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89, 215\u2013220 (2005).","journal-title":"Breast Cancer Res Treat"},{"key":"48602_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4","volume":"83","author":"A Talvensaari-Mattila","year":"1998","unstructured":"Talvensaari-Mattila, A., Paakko, P., Hoyhtya, M., Blanco-Sequeiros, G. & Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma. Cancer 83, 1153\u20131162 (1998).","journal-title":"Cancer"},{"key":"48602_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/sj.bjc.6601238","volume":"89","author":"A Talvensaari-Mattila","year":"2003","unstructured":"Talvensaari-Mattila, A., Paakko, P. & Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (mmp-2) is associated with survival in breast carcinoma. Br J Cancer 89, 1270\u20131275 (2003).","journal-title":"Br J Cancer"},{"key":"48602_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1365-2559.2007.02615.x","volume":"50","author":"E Mylona","year":"2007","unstructured":"Mylona, E. et al. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (mt1-mmp) and mmp-9 according to their localization in invasive breast carcinoma. Histopathology 50, 338\u2013347 (2007).","journal-title":"Histopathology"},{"key":"48602_CR27","first-page":"265","volume":"4","author":"D Al-Raawi","year":"2011","unstructured":"Al-Raawi, D., Abu-El-Zahab, H., El-Shinawi, M. & Mohamed, M. M. Membrane type-1 matrix metalloproteinase (mt1-mmp) correlates with the expression and activation of matrix metalloproteinase-2 (mmp-2) in inflammatory breast cancer. Int J Clin Exp Med 4, 265\u2013275 (2011).","journal-title":"Int J Clin Exp Med"},{"key":"48602_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/(SICI)1097-0215(19990719)82:2<208::AID-IJC10>3.0.CO;2-9","volume":"82","author":"MP Chenard","year":"1999","unstructured":"Chenard, M. P. et al. Presence of high levels of mt1-mmp protein in fibroblastic cells of human invasive carcinomas. Int J Cancer 82, 208\u2013212 (1999).","journal-title":"Int J Cancer"},{"key":"48602_CR29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.18632\/genesandcancer.90","volume":"6","author":"C Mehner","year":"2015","unstructured":"Mehner, C. et al. Tumor cell expression of mmp3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer 6, 480\u2013489 (2015).","journal-title":"Genes Cancer"},{"key":"48602_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3349\/ymj.2006.47.3.333","volume":"47","author":"HJ Kim","year":"2006","unstructured":"Kim, H. J., Park, C. I., Park, B. W., Lee, H. D. & Jung, W. H. Expression of mt-1 mmp, mmp2, mmp9 and timp2 mrnas in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 47, 333\u2013342 (2006).","journal-title":"Yonsei Med J"},{"key":"48602_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-959","volume":"14","author":"GE Kim","year":"2014","unstructured":"Kim, G. E. et al. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer 14, 959 (2014).","journal-title":"BMC Cancer"},{"key":"48602_CR32","doi-asserted-by":"publisher","first-page":"7621","DOI":"10.1158\/1078-0432.CCR-04-1061","volume":"10","author":"JM Pellikainen","year":"2004","unstructured":"Pellikainen, J. M. et al. Expression of matrix metalloproteinase (mmp)\u22122 and mmp-9 in breast cancer with a special reference to activator protein-2, her2, and prognosis. Clin Cancer Res 10, 7621\u20137628 (2004).","journal-title":"Clin Cancer Res"},{"key":"48602_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2189","volume":"10","author":"D Cao","year":"2008","unstructured":"Cao, D. et al. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res 10, R91 (2008).","journal-title":"Breast Cancer Res"},{"key":"48602_CR34","doi-asserted-by":"publisher","first-page":"e97804","DOI":"10.1371\/journal.pone.0097804","volume":"9","author":"QW Wu","year":"2014","unstructured":"Wu, Q. W. et al. Expression and clinical significance of matrix metalloproteinase-9 in lymphatic invasiveness and metastasis of breast cancer. PLoS One 9, e97804 (2014).","journal-title":"PLoS One"},{"key":"48602_CR35","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s004280050442","volume":"435","author":"O Brummer","year":"1999","unstructured":"Brummer, O., Athar, S., Riethdorf, L., Loning, T. & Herbst, H. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: An in situ hybridization study. Virchows Arch 435, 566\u2013573 (1999).","journal-title":"Virchows Arch"},{"key":"48602_CR36","first-page":"273","volume":"149","author":"KJ Heppner","year":"1996","unstructured":"Heppner, K. J., Matrisian, L. M., Jensen, R. A. & Rodgers, W. H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149, 273\u2013282 (1996).","journal-title":"Am J Pathol"},{"key":"48602_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0046-8177(99)90120-X","volume":"30","author":"L Nakopoulou","year":"1999","unstructured":"Nakopoulou, L. et al. Matrix metalloproteinase-1 and \u22123 in breast cancer: Correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 30, 436\u2013442 (1999).","journal-title":"Hum Pathol"},{"key":"48602_CR38","unstructured":"Hoda, S. A. Lobular carcinoma in situ and atypical lobular hyperplasia in Rosen\u2019s breast pathology (eds. Hoda, S. A., Brogi, E., Koerner, F. C. & Rosen, P. P.) 797\u2013853 (Wolters Kluwer, 2014)."},{"key":"48602_CR39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.arcmed.2010.08.010","volume":"41","author":"I Alvarado-Cabrero","year":"2010","unstructured":"Alvarado-Cabrero, I., Picon Coronel, G., Valencia Cedillo, R., Canedo, N. & Tavassoli, F. A. Florid lobular intraepithelial neoplasia with signet ring cells, central necrosis and calcifications: A clinicopathological and immunohistochemical analysis of ten cases associated with invasive lobular carcinoma. Arch Med Res 41, 436\u2013441 (2010).","journal-title":"Arch Med Res"},{"key":"48602_CR40","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1245\/s10434-011-1563-0","volume":"18","author":"SP Bagaria","year":"2011","unstructured":"Bagaria, S. P., Shamonki, J., Kinnaird, M., Ray, P. S. & Giuliano, A. E. The florid subtype of lobular carcinoma in situ: Marker or precursor for invasive lobular carcinoma? Ann Surg Oncol 18, 1845\u20131851 (2011).","journal-title":"Ann Surg Oncol"},{"key":"48602_CR41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5858\/2010-0204-OA.1","volume":"135","author":"E Downs-Kelly","year":"2011","unstructured":"Downs-Kelly, E., Bell, D., Perkins, G. H., Sneige, N. & Middleton, L. P. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med 135, 737\u2013743 (2011).","journal-title":"Arch Pathol Lab Med"},{"key":"48602_CR42","unstructured":"D\u2019Orsi, C. J. et al. Breast imaging reporting and data system: ACR BI-RADS\u2014breast imaging atlas, 4th ed. (American College of Radiology, Reston, VA, 2003)."},{"key":"48602_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"LM McShane","year":"2006","unstructured":"McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (remark). Breast Cancer Res Treat 100, 229\u2013235 (2006).","journal-title":"Breast Cancer Res Treat"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48602-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:43:18Z","timestamp":1671284598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48602-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48602-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13432"}}